CRSP
Price
$53.97
Change
-$0.39 (-0.72%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
5.35B
48 days until earnings call
Intraday BUY SELL Signals
LITS
Price
$0.86
Change
-$0.03 (-3.37%)
Updated
Jun 23, 04:08 PM (EDT)
Capitalization
30.1M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRSP vs LITS

CRSP vs LITS Comparison Chart in %
View a ticker or compare two or three
VS
CRSP vs. LITS commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Buy and LITS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (CRSP: $54.36 vs. LITS: $0.88)
Brand notoriety: CRSP and LITS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 65% vs. LITS: 47%
Market capitalization -- CRSP: $5.35B vs. LITS: $30.1M
CRSP [@Biotechnology] is valued at $5.35B. LITS’s [@Biotechnology] market capitalization is $30.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileLITS’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • LITS’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRSP and LITS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 5 TA indicator(s) are bullish while LITS’s TA Score has 6 bullish TA indicator(s).

  • CRSP’s TA Score: 5 bullish, 3 bearish.
  • LITS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both CRSP and LITS are a good buy in the short-term.

Price Growth

CRSP (@Biotechnology) experienced а +3.33% price change this week, while LITS (@Biotechnology) price change was +10.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 10, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.35B) has a higher market cap than LITS($30.1M). CRSP YTD gains are higher at: 3.661 vs. LITS (-32.977). LITS has higher annual earnings (EBITDA): -12.1M vs. CRSP (-627.33M). CRSP has more cash in the bank: 2.44B vs. LITS (9.63M). CRSP has higher revenues than LITS: CRSP (1M) vs LITS (0).
CRSPLITSCRSP / LITS
Capitalization5.35B30.1M17,787%
EBITDA-627.33M-12.1M5,184%
Gain YTD3.661-32.977-11%
P/E RatioN/AN/A-
Revenue1M0-
Total Cash2.44B9.63M25,364%
Total Debt788MN/A-
FUNDAMENTALS RATINGS
CRSP vs LITS: Fundamental Ratings
CRSP
LITS
OUTLOOK RATING
1..100
302
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4689
P/E GROWTH RATING
1..100
7342
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LITS's Valuation (74) in the Pharmaceuticals Other industry is in the same range as CRSP (91) in the Biotechnology industry. This means that LITS’s stock grew similarly to CRSP’s over the last 12 months.

LITS's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CRSP (100) in the Biotechnology industry. This means that LITS’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (98) in the Biotechnology industry is in the same range as LITS (100) in the Pharmaceuticals Other industry. This means that CRSP’s stock grew similarly to LITS’s over the last 12 months.

CRSP's Price Growth Rating (46) in the Biotechnology industry is somewhat better than the same rating for LITS (89) in the Pharmaceuticals Other industry. This means that CRSP’s stock grew somewhat faster than LITS’s over the last 12 months.

LITS's P/E Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as CRSP (73) in the Biotechnology industry. This means that LITS’s stock grew similarly to CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPLITS
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 8 days ago
71%
Declines
ODDS (%)
Bearish Trend 14 days ago
83%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signal:
Gain/Loss:
LITS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EVAX3.470.42
+13.77%
Evaxion A/S
IFRX1.900.09
+4.97%
InflaRx NV
ABT87.83-0.58
-0.66%
Abbott Laboratories
GLXY33.10-1.10
-3.22%
Galaxy Digital Inc
DAO11.11-0.94
-7.80%
Youdao

LITS and

Correlation & Price change

A.I.dvisor indicates that over the last year, LITS has been loosely correlated with GOSS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LITS jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LITS
1D Price
Change %
LITS100%
+6.87%
GOSS - LITS
45%
Loosely correlated
-2.26%
CRSP - LITS
35%
Loosely correlated
+0.50%
RXRX - LITS
32%
Poorly correlated
-2.01%
TELO - LITS
31%
Poorly correlated
-8.45%
CRBU - LITS
31%
Poorly correlated
+0.18%
More